|Bid||221.40 x 0|
|Ask||221.30 x 0|
|Day's Range||216.20 - 221.90|
|52 Week Range||85.30 - 241.70|
|Beta (5Y Monthly)||0.27|
|PE Ratio (TTM)||203.39|
|Forward Dividend & Yield||0.38 (0.17%)|
|Ex-Dividend Date||Dec 18, 2019|
|1y Target Est||230.25|
Capital increase in connection with exercise of warrants Ambu A/S issued 2,000,000 warrants in 2014, 770,000 warrants in 2015, and 419,500 warrants in November 2016. Each.
Ambu posted organic growth of 24% in Q2 as COVID-19 pandemic increased the demand for single-use devices. As a result, Ambu grew 19% in the first half of the year. Product launches for this year are progressing as planned, Ambu’s application for FDA-approval of the duodenoscope has been submitted, and further investments in the global sales organization are initiated.
Ambu pre-announces results for Q2 2019/20 with organic revenue growth of 24% and sales of 313,000 single-use endoscopes. On this basis, the guidance for organic revenue growth for the full year is upgraded from “16-22%” to “26-30%” and the number of endoscopes sold is increased from “approx. 900,000” to “more than 1 million”. Guidance for EBIT margin is suspended for now and expected to be resumed with the announcement of Q2 results on 5 May 2020.
The Malaysian authorities have granted Ambu – as a manufacturer of medical devices – exemption from the two-week movement control order that has been declared with effect from.
With the rise in Covid-19 cases, the Malaysian government has declared that the entire country will be on a movement control order starting 18 March, 2020 and expected to end on 31 March, 2020. Ambu owns and operates a manufacturing plant in Malaysia where a.o. Ambu’s single-use endoscopes are being manufactured.
Ambu A/S (CPH:AMBU B) just released its first-quarter report and things are looking bullish. It was overall a positive...
Ambu begins the year with double-digit sales growth, and a good performance across all geographies. The expansion of the sales organization as well as the preparations for.
Shareholders will be ecstatic, with their stake up 21% over the past week following Ambu A/S's (CPH:AMBU B) latest...
Ambu A/S announces today that the chairman of the board of directors Jens Bager has informed the board of directors that after 9 years of service he wishes to resign from the board of directors. Jens Bager will resign as of Ambu’s annual general meeting in December 2019. Ambu’s board of directors proposes that Lars Rasmussen is elected as new chairman of the board of directors at the annual general meeting.
In Q4, Ambu has transitioned to direct sales of aScope in the USA, and as a result full-year organic growth ends at 4% as planned. “We are in the midst of transitioning to a direct sales model in the USA to position Ambu as the leading supplier of single-use flexible endoscopy. For the past ten years, Ambu has led the creation of the market for single-use endoscopy in pulmonology, and this year we started an accelerated expansion into new endoscopy areas.
The big shareholder groups in Ambu A/S (CPH:AMBU B) have power over the company. Generally speaking, as a company...
For many, the main point of investing in the stock market is to achieve spectacular returns. While not every stock...
In Q3, Ambu has achieved solid organic growth of 10% and an EBIT margin before special items of 20.1%. The pipeline has been advanced, US approval of ENT scopes secured, and Ambu is on plan for future launch of the duodenoscope, the cystoscope and next generation aView™ monitor. In terms of commercial infrastructure, Ambu has decided to further invest in and strengthen its largest market by moving to a 100% direct sales organization for pulmonary endoscopy in the US.
Ambu has decided to invest further and strengthen its largest market by transitioning sales of aScope™ products from the US distributor. As a result, Ambu will move to a 100% direct sales organisation for pulmonary endoscopy in the US. Financial guidance is revised.
Ambu is expanding its product portfolio and commercial infrastructure. Today, we announce timelines for new aScope™ 5, a new ureteroscope, a new monitor platform that allows full HD quality and a replacement of the SC210 colonoscope for a superior scope based on classic wheel technology. Financial outlook adjusted to reflect commercial investments and new product launch timelines.